Announced this past by Mr. Mark Davis, the President and CEO of DAVISCO Foods International Inc., and the Board of MEGGLE Group of Wasserburg, Germany, represented by Drs Sil H. van der Ploeg, CEO, and Mr. Christian Sedlatschek, CFO, the companies are entering a long-term partnership for the production of pharmaceutical lactose in the US.

DAVISCO Foods is an international cheese and food ingredient company, founded in 1943, headquartered in Le Sueur, MN, a privately held, family-owned business.  DAVISCO is a company committed to technical advancement, customer service, and the production of superior quality products.

The holding group MEGGLE AG, whose headquarters are in Wasserburg, Germany, was founded in 1887 and bundles the activities of the different companies within the milk and whey-processing business group. This structure embodies flexibility and decisiveness on the one hand and the traditional character of the dairy with its long history of milk-processing on the other. The Business Group Excipients & Technology is considered the leading producer of pharmaceutical lactose and excels in particular in offering High-Tech, innovative excipients to the pharmaceutical industry worldwide.

DAVISCO will expand its existing lactose production at the Le Sueur facility to accommodate additional production lines for the production of pharmaceutical lactose utilizing state-of-the-art processing technology. Meggle will provide the technical marketing, sales, and distribution for the pharmaceutical lactose products.

“DAVISCO Foods Intl. Inc. is excited and honored to engage in a joint venture with the Meggle Company to produce pharmaceutical lactose products. We have had a close and rewarding relationship for years with Meggle and have respected and admired their many achievements. The joint venture will produce the same high-quality products and provide the same service that Meggle has historically produced and provided,” said Mr. Mark Davis, President Davisco Food International Inc.

“MEGGLE highly appreciates the partnership with DAVISCO. This is an important step in our strategy to expand our capacities and at the same time to offer our customers worldwide the security of a second production site,” added Dr. Sil H. van der Ploeg, CEO of MEGGLE.

Source: Web of Drug Delivery Technology